One Case of Skin Pigmentation Induced by Polymyxin B for Injection

doi:10.19803/j.1672-8629.2021.05.18

Abstract

Abstract: Objective To analyze the possible factors of skin pigmentation caused by polymyxin B for injection and promote the rational use of drugs in clinic. Methods The diagnosis and treatment of a case of skin pigmentation caused by polymyxin B were analyzed and combined with literature search to explore the mechanism and countermeasures of skin pigmentation induced. Results On the 14th day after the patient's intravenous administration of polymyxin B, the patient's head and neck skin were observed to be pigmented. Considering the combination of sirolimus blood concentration accumulation, reduce the sirolimus dose by half and monitor the drug Blood concentration. It was found that sirolimus was within the effective blood concentration range. The infection was controlled on the 30th day, and polymyxin B was discontinued. At this time, the patient's body skin was dark brown, and the patient's body skin was followed up for 5 months. Significantly weaker than before, but did not return to normal. Conclusion Alternative treatment options should be selected for polymyxin B-induced skin pigmentation. If continued use is warranted, simultaneous or sequential use of neurotoxic or nephrotoxic drugs should be avoided, and renal function and polymyxin B blood levels should be monitored during treatment.

Key words: polymyxin B, skin pigmentation, drug-related side effects

CLC Number:

R969.3

CHEN Jianshou, WANG Min. One Case of Skin Pigmentation Induced by Polymyxin B for Injection[J]. Chinese Journal of Pharmacovigilance, 2021, 18(5): 489-491.

References

[1] Storm DR,Rosenthal KS,Swanson PE.Polymyxin and related peptide antiibiotics[J].Annu Rev Biochem,1977,46:723-763.
[2] Hu FP,Guo Y,Zhu DM,et al.Antimicrobial resistance profile of clinical isolates in hospitals across China:report from the CHINET Surveillance Program,2017[J].Chinese Journal of Infection and Chemotherapy(中国感染与化疗杂志),2018,18(3):241-251.
[3] Chinese XDR Consensus Working Group,Guan XD,He LX,et al.Laboratory diagnosis,clinical management and infection control of the infections caused by extensively drug-resistant Gram-negative bacilli:a Chinese conse-nsus statement[J].Clinical Microbiology and Infection,2016:22:S15-S25.
[4] Tran TB,Velkov T,Nation RL,et al.Pharmacokinetics-pharmacodynamics of colistin and Polymyxin B:are we there yet?[J].Int J Antimicrob Agents,2016,48(6):592-597.
[5] Chen Y,Mai SX,Wen XR,et al.Literature analysis of skin pigmentation in adult patients induced by polymyxin B[J].Chinese Journal of Drug Applic-ation and Monitoring(中国药物应用与监测),2019,16(3):161-164.
[6] Mattos KPH,Cintra ML,Gouvea IR,et al.Skin hyperpigmentation following intravenous polymyxin B treatment associated with melanocyte activation and inflammatory process[J].J Clin Pharm Ther,2017,42(5):573-578.
[7] Bushby SR,Green AF.The release of histamine by polymyxin b and polymyxine[J].British Journal of Pharmacology and Chemotherapy,1955,10(2):215-219.
[8] Yoshida M,Takshashi Y,Inoue S.Histamine induces melanogenesis and morphologic changes by protein kinase A activation via H2 receptors in human normal melanocytes[J].J Invest Dermatol,2000,114(2):334-342.
[9] Slater D,Histologic diagnosis of inflammatory skin diseases An algorithmic method based on pattern analysis,3 rdedu[J].Histopathology,2005,47(6):707-708.
[10] Zheng GH,Cao L,Che ZQ,et al.Polymyxin B-induced skin hyperpigmentation:a rare case report and literature review.[J].BMC pharmacology &toxicology,2018,19(1):41.
[11] Knueppel RC,Rahimian J.Diffuse cutaneous hyperpingmentation due to tigecycline or polymyxin B[J].Clin Infect Dis,2007,45(1):136-138.
[12] Kronenfeld MA,Thomas SJ,Turndorf H.Recurrence of neuromuscular blockade after reversalofvecuronium in a patient receiving polymyxin-amikacin sternal irrigation[J].Anesthesiology,1986 (65):93-94.
[13] Lindesmith LA,Baines RD Jr,Bigelow DB,et al.Reversible respiratory paralysis associated with polymyxintherapy[J].Ann Intern Med,1968(68):318-327.
[14] Fogdall RP,Miller RD.Prolongation of a pancuronium-induced neuro-muscular blockade by polymyxin B[J].Anesthesiology,1974 (40):84-87.
[15] Gebbie D.Colistimethate and curare:a case report[J].Anesth Analg,1971 (50):109-111.
[16] Zauder HL,Barton N,Bennett EJ,et al.Colistimethate as a cause of postoperative apnoea[J].Can AnaesthSoc J,1966 (13):607-610.
[17] Justin R,LenhardT,Roger L,et al.Synergistic combinations of polymyxins[J].International Journal of Antimicrobial Agents,2016,48(6):241-244.
[18] Liang BB,Wang R,Wang J,et al.Bibliometric analysis of polymyxin nephrotoxicity literature based on Web of Science[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2015,12(12):756-759.
[19] Oliveir AM,Prado GVB,Costa SF,et al.Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity[J].Diagn MicrInfec Dis,2009,65(4):431-434.
[20] Falagas ME,Rizos M,Bliziotis IA,et al.Toxicity after prolonged (more than four weeks) administration of intravenous colistin[J].BMC Infect Dis,2005(5):1.